Response to PBAC regarding the listing of alprazolam


Last updated 3 June 2019

Summary

Date: 23 March 2016

The RACGP supports the Pharmaceutical Benefits Advisory Committee (PBAC) proposed changes to the PBS listing of alprazolam.

The RACGP supports the proposed changes of:

  • removing the 2mg strength of alprazolam from the PBS; and
  • reducing the pack size from 50 tablets to 10 for the remaining strengths, will nil repeats.

Read the full response

Response to PBAC regarding the listing of alprazolam (PDF 88 KB)

Advertising

Advertising